Ed Silverman at Pharmalot has a piece on a perennial source of confusion for anyone outside the drug industry (and too many inside it): the difference between Merck and Merck. One of them gets called "Merck-Darmstadt" or just "German Merck" by some people - I've never heard "Merck KGgA" used in spoken English. Show More Summary
Merck KGgA, the German drug maker, is concerned about ongoing confusion over the Merck name, which is shared by the U.S. drug maker.
A generic version of Vicodin, a powerful prescription painkiller, was the most widely prescribed drug to Medicare beneficiaries in 2013.
Good morning, everyone, and welcome to another working week. Another weekend respite has flown by, although we hope it was invigorating because, as you know, the routine of meetings and deadlines and what not has now returned. This means...Show More Summary
in 2013 I mentioned the efforts by the Reproducibility Initiative to redo studies in the field of experimental psychology. That's a timely idea, since there have been many questions recently about the rigor of some of its results - for a fresh example, see here. Now the results are in for the first 100 studies (here's an article at Nature News). Show More Summary
8th Summit on Managed Care Market StrategiesJune 22-23, 2015 | Philadelphia, PAwww.cbinet.com/managedcareAs one of the longest running annual conferences dedicated to managed markets professionals, Managed Care Market Strategies offers...Show More Summary
An Express Scripts unit has agreed to pay $60 million to resolve allegations by U.S. authorities that it participated in a kickback scheme with Novartis that caused federal health care programs to pay for a medicine based on false claims, according to court documents.
Here's a paper on recent clinical trials in Nature Reviews Drug Discovery that reports some changes. It's just concentrating on the trials that began in the 2005-2009 period, and in case you're wondering, over 14,000 trials started during that period. Show More Summary
Pharma marketers cannot communicate with each other without using "buzzwords." Some critics suggest, however, that some of these buzzwords alienate patients and physicians (see, for example, "Do Marketing Buzzwords Affect Pharma's Reputation Among Patients & Physicians?"). Show More Summary
Happy May Day! As much of the world celebrates the worker, here we toil to bring you this week’s latest. We are well into the second quarter of the year – hard to believe – and are having those kinds … Continue reading ?
Dr Peter Parry is an Australian child & adolescent psychiatrist who has researched the "Pediatric Bipolar Disorder" diagnosis emanating from the USA, a diagnosis completely at odds with his training and clinical experience in Australian child and adolescent mental health. Show More Summary
Tucked into a Congressional draft bill called 21st Century Cures for jump starting medical innovation is a passage that would undo a portion of a federal law requiring drug and device makers to disclose payments to physicians.
The pharmaceutical is on edge as more local governments adopt take-back programs that require drug makers pay the costs.
The latest comings and goings in the pharmaceutical industry.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to fire up the retooled lawncutter, spend time with assorted short people and catch up on our reading, when we are not napping. Show More Summary
In the long-running saga of getting a stapled peptide to work as a drug, Aileron Therapeutics was last heard from raising money for their p53 candidate. Now comes word that the company is basically going all-in with that one, raising yet more cash and gearing up for some definitive human trials. I wish them luck. Show More Summary
Today’s guest post comes from Scott Pribyl, CEO of SamplifyRx. Scott discusses RapidPA Score™—an intriguing scoring system for specialty drug prior authorizations. He also reviews the benefits of a cloud-based tool that allows for near real-time prior authorization (NRTPA) approvals. Show More Summary
The following facetious FAQ list is based on a WebMD FAQ list ("Here’s what you need to know" about a "New Drug [that] Zaps Double Chin"). WebMD appears to be vying for notoriety as the Dr. OZ of the Internet! New Drug Kybella Zaps Double Chin: Facetious FAQ